<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors></authors><secondary-authors><author><style face="normal" font="default" size="100%">Bhatt, Deepak</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">CHARISMA</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2006</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2006-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">12-12</style></pages><abstract><style  face="normal" font="default" size="100%">CHARISMA (Clopidogrel for High Atherothrombotic Risk, Ischemic Stabilization, Management, and Avoidance) is the first clinical trial to evaluate long-term effectiveness of clopidogrel plus aspirin in a population of high-risk patients, including symptomatic individuals with documented disease. Principal investigator Deepak Bhatt, MD, of the Cleveland Clinic Cardiovascular Coordinating Center, presented results from more than 15,000 study participants followed for a median of 2.3 years.</style></abstract><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">6</style></volume></record></records></xml>